The Promise of Epigenomic Therapeutics in Pancreatic Cancer
Authors:
Open Access
- 23 June 2016
- journal article
- review article
- Published by Taylor & Francis in Epigenomics
- Vol. 8 (6) , 831-842
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is often viewed to arise primarily by genetic alterations. However, today we know that many aspects of the cancer phenotype require a crosstalk among these genetic alterations with epigenetic changes. Indeed, aberrant gene expression patterns, driven by epigenetics are fixed by altered signaling from mutated oncogenes and tumor suppressors to define the PDAC phenotype. This conceptual framework may have significant mechanistic value and could offer novel possibilities for treating patients affected with PDAC. In fact, extensive investigations are leading to the development of small molecule drugs that reversibly modify the epigenome. These new ‘epigenetic therapeutics’ discussed herein are promising to fuel a new era of studies, by providing the medical community with new tools to treat this dismal disease.Keywords
Funding Information
- National Institutes of Health (R01 CA178627, R01 DK52913)
- Mayo Clinic Center for Cell Signaling in Gastroenterology (P30DK084567)
- Mayo Clinic SPORE in Pancreatic Cancer (P50 CA102701)
This publication has 60 references indexed in Scilit:
- BLUEPRINT to decode the epigenetic signature written in bloodNature Biotechnology, 2012
- Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain FamilyCell, 2012
- Readers of histone modificationsCell Research, 2011
- Histone arginine methylationFEBS Letters, 2010
- MicroRNAs: Target Recognition and Regulatory FunctionsCell, 2009
- Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?Nature Reviews Genetics, 2008
- Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancersMolecular Carcinogenesis, 2008
- An elaborate pathway required for Ras-mediated epigenetic silencingNature, 2007
- Expression profiling identifies microRNA signature in pancreatic cancerInternational Journal of Cancer, 2006
- The language of covalent histone modificationsNature, 2000